AHAmir Haze

Amir Haze

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amir Haze has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recombinant Human Amelogenin Protein Enhances Healing of Osteochondral Injury in a Goat Model

    by Omer Helwa‐Shalom, Hani Nevo, Tarek Nasrawy, Masha Galiner, Azraq Yusef, Keren Ben‐David, Shany Ivon Markowitz, Yechiel N. Gellman, Shaul Beyth, Hagit Sacks, et al.

    Osteochondral injuries are common, painful, and lack natural healing abilities. Previous studies demonstrated that recombinant human amelogenin promotes osteochondral repair in rat knee injuries, including improved defect filling and formation of hyaline cartilage. Here, we aimed to evaluate the efficacy and safety of Remelix®, a novel recombinant human amelogenin–based product, in a large animal goat model. Acute osteochondral injuries were created in the weight‐bearing region of the medial femoral condyle in thirteen goats. Seven goats received Remelix® at a protein concentration of 0.5 mg/mL, with the contralateral knee applied with PX 407 carrier alone. An additional six goats received Remelix® at 0.25 mg/mL, while contralateral knees were treated with normal saline. Potential adverse effects, along with evaluation of osteochondral healing were assessed. Healing was assessed 24 weeks post‐treatment using magnetic resonance imaging (MRI), macroscopic evaluation, and histological and immunohistochemical analyses. No adverse effects were observed. Both Remelix® concentrations resulted in substantial healing of cartilage and subchondral bone. Histological analyses demonstrated improved tidemark formation, predominantly hyaline cartilage filling in the deeper layers of the defect with extension toward the superficial zone, and reduced subchondral bone abnormalities. MRI and macroscopic evaluations revealed a continuous repair surface with good integration at the defect margins. In contrast, PX 407 and saline‐treated control knees exhibited inferior repair, characterized by mainly fibrous cartilage, heterogeneous MRI signal intensity, and lower histological scores. Overall, Remelix® substantially improved osteochondral healing in a goat model without observable adverse effects, supporting its potential for further evaluation in human clinical studies.

  • Open Access

    Recombinant Human Amelogenin Protein Enhances Tendon‐To‐Bone Healing in a Rat Rotator Cuff Tear Model

    by Shany Ivon Markowitz, Shlomi Bulkowstein, Michael Emanuel, Oleg Dolkart, Yariv Goldstein, Omer Helwa‐Shalom, Chen Yochanan, Yechiel N. Gellman, Anat Blumenfeld, Hani Nevo, et al.

    Rotator cuff tears (RCTs) often require surgical intervention; however, surgical outcome is frequently insufficient due to poor healing of the tendon‐bone enthesis, leading to high retear rates. Previously, the recombinant human amelogenin protein (rHAM + ) regenerated injured or diseased musculoskeletal tissues including ligaments and osteochondral injuries. We therefore hypothesized that rHAM + can also induce regeneration of the biomechanical and structural properties of the enthesis. The right shoulder infraspinatus tendon of 75 rats was fully‐transected, and treated either with 0.5 mg/mL rHAM + dissolved in propylene glycol alginate (PGA) carrier ( n  = 30), or with PGA carrier alone ( n = 30). Fifteen unoperated rats were additionally evaluated. Four‐ and eight‐weeks posttreatment, the degree of regeneration was evaluated using biomechanical and histological analyses. rHAM + induced full recovery of biomechanical properties 8 weeks posttreatment, with the transected tendon demonstrating similar averaged tensile strength as the unoperated contralateral tendon, while PGA brought about substantially inferior biomechanical outcome. Eight weeks after treatment with rHAM + , progressive structural improvement was observed, including parallel type I collagen fibers with orientation and width similar to the uninjured group, restoration of the fibrocartilage zone, bone ingrowth, and a detectable tidemark, contrary to poor tissue maturation of the PGA‐treated tendons. Furthermore, rHAM + led to significantly less fatty degeneration of the infraspinatus muscle compared to PGA. rHAM + induced regeneration of biomechanical strength and promoted maturation of the enthesis of fully transected rat RCT. Therefore, we recommend further evaluation of amelogenin as possible adjunct therapeutic strategy to improve the healing and reduce retears in clinical RC repair.


  • Open Access

    Amelogenin Null Mice Develop Osteoarthritis, While Its Application Mitigates Disease Phenotypes in a Rat Model

    by Omer Helwa‐Shalom, Yarden Kahlon‐Suki, Shany Ivon Markowitz, Koby Goren, Dekel Shilo, Shira Schoonmaker, Chen Yochanan, Yechiel N. Gellman, Shaul Beyth, Dan Deutsch, et al.

    Previous studies have demonstrated that recombinant human amelogenin protein (rHAM + ) promotes healing of injured articular cartilage, subchondral bone, and skeletal ligaments. Therefore, we speculated that amelogenin may play a role in osteoarthritis (OA) development. Aged amelogenin‐null and wild‐type mice underwent micro‐computed tomography (micro‐CT) and histological analyses to assess OA‐related changes. Additionally, OA was induced in rat knees via destabilization of the medial meniscus, followed by treatment with 0.5 mg/mL rHAM + dissolved in propylene glycol alginate (PGA) or PGA alone. Magnetic resonance imaging (MRI) and histological analyses were performed. Twenty‐three‐month‐old amelogenin‐null mice exhibited severe OA features, including cartilage loss, joint space narrowing, and osteophyte formation, whereas wild‐type mice showed only mild, age‐related changes. OA pathology was evident in 12‐month‐old amelogenin‐null mice, by increased matrix metalloproteinase‐13 (MMP‐13) and decreased type II collagen expression. In osteoarthritic rats, MRI analyses demonstrated that treatment with rHAM + delayed disease progression and improved OA phenotypes. Twenty‐four weeks posttreatment, the levels of type II collagen increased, while MMP‐13 and type X collagen decreased. MMP‐13 reduction was detected as early as 2 weeks posttreatment, contributing to cartilage preservation. Furthermore, similar to the known effect of rHAM + in acute injuries, recruitment of CD105‐positive mesenchymal stem cells to the cartilage was detected 5 days posttreatment. Lack of amelogenin led to the development of osteoarthritic phenotypes, whereas in the induced osteoarthritis model, a single application of amelogenin inhibited joint deterioration and partially healed osteoarthritic damage compared with the control. These findings highlight the potential of amelogenin as a disease‐modifying agent for OA.


  • Comparison of patient specific implant reconstruction vs conventional titanium mesh reconstruction of orbital fractures using a novel method

    by Andrei Krasovsky, Ahmad Hija, Nidal Zeineh, Tal Capucha, Amir Haze, Omri Emodi, Adi Rachmiel, Dekel Shilo


  • Open Access

    Regeneration of injured articular cartilage using the recombinant human amelogenin protein

    by Omer Helwa-Shalom, Faris Saba, Elad Spitzer, Salem Hanhan, Koby Goren, Shany I. Markowitz, Dekel Shilo, Nissim Khaimov, Yechiel N. Gellman, Dan Deutsch, et al.

    Aims: Cartilage injuries rarely heal spontaneously and often require surgical intervention, leading to the formation of biomechanically inferior fibrous tissue. This study aimed to evaluate the possible effect of amelogenin on the healing process of a large osteochondral injury (OCI) in a rat model.Methods: A reproducible large OCI was created in the right leg femoral trochlea of 93 rats. The OCIs were treated with 0.1, 0.5, 1.0, 2.5, or 5.0 μg/μl recombinant human amelogenin protein (rHAM+) dissolved in propylene glycol alginate (PGA) carrier, or with PGA carrier alone. The degree of healing was evaluated 12 weeks after treatment by morphometric analysis and histological evaluation. Cell recruitment to the site of injury as well as the origin of the migrating cells were assessed four days after treatment with 0.5 μg/μl rHAM+ using immunohistochemistry and immunofluorescence.Results: A total of 12 weeks after treatment, 0.5 μg/μl rHAM+ brought about significant repair of the subchondral bone and cartilage. Increased expression of proteoglycan and type II collagen and decreased expression of type I collagen were revealed at the surface of the defect, and an elevated level of type X collagen at the newly developed tide mark region. Conversely, the control group showed osteoarthritic alterations. Recruitment of cells expressing the mesenchymal stem cell (MSC) markers CD105 and STRO-1, from adjacent bone marrow toward the OCI, was noted four days after treatment.Conclusion: We found that 0.5 μg/μl rHAM+ induced in vivo healing of injured articular cartilage and subchondral bone in a rat model, preventing the destructive post-traumatic osteoarthritic changes seen in control OCIs, through paracrine recruitment of cells a few days after treatment.Cite this article: Bone Joint Res 2023;12(10):615–623.


  • Open Access

    Association of Inpatient Glucose Measurements With Amputations in Patients Hospitalized With Acute Diabetic Foot

    by Shahar Peled, Rena Pollack, Ofer Elishoov, Amir Haze, Avivit Cahn

    Context: The association of inpatient glucose measurements with amputations in patients admitted with acute diabetic foot has not been described. Objective: To evaluate the relationship of hyperglycemia, hypoglycemia, and glucose variability during hospitalization with amputations in patients hospitalized with acute diabetic foot. Design: Retrospective cohort study. Setting: Academic tertiary hospital. Patients: We reviewed demographic, clinical, laboratory, and point-of-care glucose data in patients hospitalized with acute diabetic foot in the Diabetic Foot Unit during 2015 through 2017. Main Outcome Measures: The primary outcomes were any or major amputations during hospitalization. Secondary outcomes included length of hospitalization and in-hospital mortality. Results: During the study period, 418 patients were hospitalized in the Diabetic Foot Unit and 45,496 glucose measurements were taken. Patients experiencing any hyperglycemia and any or severe hypoglycemia were more likely to undergo any or major amputations during hospitalization. High glycemic variability was associated with major amputations. Peripheral vascular disease (PVD), high Wagner score, and hypoglycemia were independent predictors of amputations. Older age, PVD, previous amputation, elevated white blood cell level, high Wagner score, and hypoglycemia were independent predictors of major amputations. Conclusions: In-patient hypoglycemia emerged as an independent risk factor for any and major amputations. Although it is unclear whether hypoglycemia directly contributes to adverse outcomes or is simply a biomarker of disease severity, efforts to minimize in-hospital hypoglycemic events are warranted.